104010-92-6

Basic information

• Product Name: D,L-N,N'-Di-tert-butoxycarbonyl-2,3-diaminopropionic acid
• Synonyms: 2,3-Bis[(tert-butoxycarbonyl)amino]propionic acid;D,L-N,N'-Di-tert-butoxycarbonyl-2,3-diaminopropionic acid;N,N'-Bis(tert-butoxycarbonyl)-2,3-diaminopropionic acid;N,N'-Bis-Boc-2,3-diaMinopropionic acid;2,3-Bis((tert-butoxycarbonyl)amino)propanoic acid
• CAS NO: 104010-92-6
• Molecular Formula: C₁₃H₂₄N₂O₆
• Molecular Weight: 304.33946
• Mol File: 104010-92-6.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 469.0±40.0 °C(Predicted)
• Appearance: /
• Density: 1.157
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.69±0.10(Predicted)
• CAS DataBase Reference: D,L-N,N'-Di-tert-butoxycarbonyl-2,3-diaminopropionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: D,L-N,N'-Di-tert-butoxycarbonyl-2,3-diaminopropionic acid(104010-92-6)
• EPA Substance Registry System: D,L-N,N'-Di-tert-butoxycarbonyl-2,3-diaminopropionic acid(104010-92-6)

Safety Data

• Hazardous Substances Data: 104010-92-6(Hazardous Substances Data)

Usage

General Description

D,L-N,N'-Di-tert-butoxycarbonyl-2,3-diaminopropionic acid is a chemical compound commonly used in the synthesis of peptides and peptoids. It is a derivative of 2,3-diaminopropionic acid, which is an important building block for the creation of various bioactive molecules. The tert-butoxycarbonyl (Boc) protecting group attached to the amine groups of the diaminopropionic acid molecule helps to prevent unwanted reactions and allows for selective deprotection during the synthesis process. D,L-N,N'-Di-tert-butoxycarbonyl-2,3-diaminopropionic acid is an important tool in the field of medicinal chemistry, as it allows for the controlled assembly of specific peptide sequences and the creation of potential drug candidates. Its use in peptide synthesis makes it a valuable chemical for research and development in the pharmaceutical industry.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 18635-45-5 D,L-α,β-diaminopropionic acid monohydrobromide 
• 515-94-6 2,3-diaminopropanoic acid 
• 109461-78-1 ethyl 2,3-bis[(tert-butoxycarbonyl)amino]propionate 
• 54897-59-5 2,3-diaminopropanoic acid hydrochloride 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 

Downstream Products

• 1607465-16-6 N,N-di-tert-butoxycarbonyl[N-(2-N-acetylamino-4-(3-aminophenyl)thiazole)]-2,3-diaminopropanamide 
• 1443511-08-7 4β-N-[2'',3''-bis(tert-butoxycarbonylamino)propanoyl]-4'-O-demethyl-podophyllotoxin 
• 1443511-07-6 4β-N-[2'',3''-bis (tert-butoxycarbonylamino)propanoyl]-podophyllotoxin 
• 1312306-37-8 (R,S)-N-benzyl 2,3-bis(t-butoxycarbonylamino)propionamide 
• 109273-25-8 2,3-di(butyloxycarbonylamino)propionic acid benzyl ester 
• 113647-56-6 [2-tert-Butoxycarbonylamino-3-oxo-3-(4-phenyl-piperidin-1-yl)-propyl]-carbamic acid tert-butyl ester 
• 875783-58-7 {2-tert-butoxycarbonylamino-2-[2-(4-sulfamoyl-phenyl)-ethylcarbamoyl]-ethyl}-carbamic acid tert-butyl ester 
• 225115-99-1 ({3-(2-{2-[2-(2,3-bis-tert-butoxycarbonylamino-propionylamino)-ethoxy]-ethoxy}-ethylcarbamoyl)-5-[(bis-ethoxycarbonylmethyl-amino)-methyl]-benzyl}-ethoxycarbonylmethyl-amino)-acetic acid ethyl ester 

Relevant articles and documents

Selective and monofunctional guanosine 5′-monophosphate binding by chloro[3-(2,3-diaminopropionylamino)propionic acid]-(dimethyl sulfoxide)platinum(II) complex

A new complex of chloro[3-(2,3-diaminopropionylamino)propionic acid](dimethyl sulfoxide)platinum(II) ([PtCl-(dmso)(Hdapap)]CF 3CO2·2H2O) was synthesized and characterized. Among a series of nucleic acids, the selective and 1:1 binding between [PtCl(dapap)(dmso)] and a guanosine 5′-monophosphate ion (Hgmp-) in an aqueous solution at pH 4.0 (20 mmol dm-3, each) was achieved by conducting ESI-MS and NMR experiments. This reaction included the initial chloride ion displacement by H2O, followed by metal coordination to the NT-position of the guanine base. The latter step was not affected in the case of guanosine-3′,5′-cyclic monophosphate ion (cgmp-), indicating that the phosphate-Pt binding can be ruled out in this system. In order to monitor the binding reaction of [PtCl(dapap)(dmso)] with several nucleic acids, time-course 1H and 31PNMR experiments were performed at 25 °C. Changes in the NMR chemical shifts of H8, H1′, and phosphate signals in Hgmp- upon the addition of [PtCl(dapap)(dmso)] revealed that two products finally remained. Since the synthetic dapap ligand could regulate the reactivity of a ligand coordinated to the Pt-center in [PtCl(dapap)(dmso)], this may arise from the presence of cis- and trans-isomers of [PtCl(dapap)-(dmso)] in solution.

Synthesis and Evaluation of Manganese(II)-Based Ethylenediaminetetraacetic Acid-Ethoxybenzyl Conjugate as a Highly Stable Hepatobiliary Magnetic Resonance Imaging Contrast Agent

In this study, we designed and synthesized a highly stable manganese (Mn2+)-based hepatobiliary complex by tethering an ethoxybenzyl (EOB) moiety with an ethylenediaminetetraacetic acid (EDTA) coordination cage as an alternative to the well-established hepatobiliary gadolinium (Gd3+) chelates and evaluated its usage as a T1 hepatobiliary magnetic resonance imaging (MRI) contrast agent (CA). This new complex exhibits higher r1 relaxivity (2.3 mM-1 s-1) than clinically approved Mn2+-based hepatobiliary complex Mn-DPDP (1.6 mM-1 s-1) at 1.5 T. Mn-EDTA-EOB shows much higher kinetic inertness than that of clinically approved Gd3+-based hepatobiliary MRI CAs, such as Gd-DTPA-EOB and Gd-BOPTA. In addition, in vivo biodistribution and MRI enhancement patterns of this new Mn2+ chelate are comparable to those of Gd3+-based hepatobiliary MRI CAs. The diagnostic efficacy of the new complex was demonstrated by its enhanced tumor detection sensitivity in a liver cancer model using in vivo MRI.

Synthesis, characterization, and anticancer activity of benzothiazole aniline derivatives and their platinum (Ii) complexes as new chemotherapy agents

We describe the synthesis, characterization, molecular modeling, and in vitro anticancer activity of three benzothiazole aniline (BTA) ligands and their corresponding platinum (II) complexes. We designed the compounds based on the selective antitumor properties of BTA, along with three types of metallic centers, aiming to take advantage of the distinctive and synergistic activity of the complexes to develop anticancer agents. The compounds were characterized using nuclear magnetic resonance spectrometry, Fourier transform infrared spectroscopy, mass spectrometry, elemental analysis, and tested for antiproliferative activity against multiple normal and cancerous cell lines. L1, L2, and L1Pt had better cytotoxicity in the liver, breast, lung, prostate, kidney, and brain cells than clinically used cisplatin. Especially, L1 and L1Pt demonstrated selective inhibitory activities against liver cancer cells. Therefore, these compounds can be a promising alternative to the present chemotherapy drugs.

SPHINGOSINE ANALOGS AND USE THEREOF AGAINST BACTERIAL LUNG INFECTIONS

Provided herein is a group of sphingosine analogs, useful in the treatment of bacterial infections in mucosal surfaces such as lungs, caused by pathogenic bacteria which are typical to disorders and diseases such as CF and COPD.